Numerous clinical trials using HER2-targeting therapeutic vaccines (e.g., peptide vaccines, protein vaccines, DNA vaccines and cell type vaccines) have been tested for their therapeutic outcomes in breast cancer patients (reviewed in [11]). This evidence concerns the gene ERBB2 and breast carcinoma.